All In Biotech

Free tool

FAERS Monitor: Xeomin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125360 or its brand name (Xeomin, Incobotulinumtoxina). Reports on generic versions are filed under their own applications.

Reports

5,818

Serious

787

14% of reports

Hospitalization

215

Death reported

110

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,876
  • off label use1,218
  • therapeutic response decreased761
  • injection site pain343
  • overdose237
  • product preparation issue216
  • injection site swelling213
  • headache195
  • product use in unapproved indication195
  • pain181
  • injection site erythema140
  • eyelid ptosis134
  • injection site mass134
  • dysphagia127
  • incorrect route of product administration115

Reports by year received

View as table
YearReports
20082
201116
201266
201316
201420
2015174
2016354
2017242
2018368
2019315
2020394
2021542
2022555
2023651
2024830
2025754
2026519

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,341 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product preparation issueSignal216123.1107.725,181
eyelid ptosisSignal13448.340.86,081
therapeutic response decreasedSignal76145.943.033,086
incorrect route of product administrationSignal11524.420.42,543
injection site massSignal13413.111.11,489
injection site swellingSignal21310.18.81,734
drug ineffectiveSignal1,8765.25.06,683
off label useSignal1,2185.04.84,099
dysphagiaSignal1274.84.1385
injection site erythemaSignal1404.13.5324
injection site painSignal3434.03.7794
overdoseSignal2374.03.5530
product use in unapproved indicationSignal1952.82.5234
headache1951.11.03
pain1811.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.